Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy Evaluation of Submucosal Injection of Gemcitabine in Preventing Recurrence of Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized, Single-Blind, Multicenter Clinical Study

NCT07198451 is registered in ClinicalTrials.gov with Shanghai University of Traditional Chinese Medicine as lead sponsor.

NCT NCT07198451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07198451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy Evaluation of Submucosal Injection of Gemcitabine in Preventing Recurrence of Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized, Single-Blind, Multicenter Clinical Study
Lead sponsor
Shanghai University of Traditional Chinese Medicine
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
October 31, 2025
Completion date
June 30, 2028
Enrollment
320 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non muscle invasive bladder cancer